Chief Executive Officer
Chris is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020.
Prior to joining ONK Therapeutics Chris was CEO of Cell Medica, an early stage cell therapy company exploring CAR therapy based on natural killer T cells. Prior to that, he was Head of Europe at Kite Pharma (acquired by Gilead),where he was responsible for building the European organization from the ground up and full European commercialization of the CAR-T therapy axicabtagene ciloleucel.
Previous roles over more than 25 years in the biopharma industry, span senior leadership positions including, CEO of Avantogen Oncology (key asset acquired by SciClone Pharmaceuticals), General Management roles at Amgen, and senior global and regional commercial leadership roles in the field of immuno-oncology at Bristol-Myers Squibb.
Chris received a BSc in Biochemistry from the University of Kent, Canterbury, England.